6949.TW Pell Bio-Med Technology Co., Ltd.
- Market cap
- TWD 49.2B
- P/E
- -
- P/B
- 19.14x
- ROE
- -12.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6949.TW undervalued?
Graham numberThe Graham number of Pell Bio-Med Technology Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pell Bio-Med Technology Co., Ltd. fundamental analysis
No fundamental analysis for Pell Bio-Med Technology Co., Ltd. yet.
Pell Bio-Med Technology Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pell Bio-Med Technology Co., Ltd.
Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen recombinant T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is al…
Full company profilePell Bio-Med Technology Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pell Bio-Med Technology Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 14.0M | 17.2M | 18.0M | 19.6M | 31.4M | 30.6M |
| Gross Profit | -34.5M | -42.3M | -26.1M | -12.3M | -4.39M | -6.01M |
| Operating Income | -196M | -236M | -411M | -413M | -467M | -396M |
| EBITDA | -157M | -199M | -353M | -346M | -420M | -315M |
| Net Income | -189M | -230M | -399M | -389M | -424M | -331M |
| EPS | -0.28 | -0.29 | -0.43 | -0.34 | -0.36 | -0.25 |
| Balance Sheet | ||||||
| Total Assets | 394M | 1.04B | 1.42B | 1.74B | 2.11B | 3.16B |
| Total Liabilities | 169M | 230M | 237M | 459M | 418M | 334M |
| Shareholders' Equity | 225M | 801M | 1.17B | 1.18B | 1.42B | 2.57B |
| Cash & Short-term Investments | 116M | 708M | 1.11B | 1.14B | 1.31B | 2.27B |
| Total Debt | 141M | 203M | 173M | 365M | 237M | 232M |
| Cash Flow | ||||||
| Operating Cash Flow | -109M | -156M | -180M | -260M | -281M | -483M |
| Capital Expenditure | 14.5M | 8.50M | 16.5M | 264M | 228M | 156M |
| Free Cash Flow | -123M | -164M | -196M | -524M | -509M | -639M |
| Ratios | ||||||
| ROE | -84.0% | -28.7% | -34.1% | -33.0% | -29.8% | -12.9% |
| ROA | -48.0% | -22.0% | -28.1% | -22.3% | -20.1% | -10.5% |
| Net Profit Margin | -1,351.9% | -1,341.3% | -2,211.3% | -1,983.7% | -1,349.1% | -1,080.3% |
| Debt to Equity | 0.63x | 0.25x | 0.15x | 0.31x | 0.17x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pell Bio-Med Technology Co., Ltd. dividends
Pell Bio-Med Technology Co., Ltd. has not paid dividends in the last 5 fiscal years.
Last stock split: 20000:1000 on Aug 27, 2026.
Who owns Pell Bio-Med Technology Co., Ltd.
- Insiders 0.00%
- Institutions 0.73%
- Public & others 99.27%
- Shares outstanding 1.31B
- Free float 786M
Pell Bio-Med Technology Co., Ltd. company profile
- Company name
- Pell Bio-Med Technology Co., Ltd.
- Ticker
- 6949.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 87, Xinhu 2nd Rd., Taipei, Taiwan
- Phone
- 886 2 8791 1789
- Website
- pellbmt.com
About Pell Bio-Med Technology Co., Ltd.
Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen recombinant T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is also involved in the phase 1/2 multicenter study to evaluate the safety and efficacy of CD19-targeted chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell lymphoma; a follow-up study of lentiviral-based gene-modified immune cell therapy. The company was founded in 2017 and is based in Taipei, Taiwan.
Pell Bio-Med Technology Co., Ltd. management
3- Mr. Cheng Long LinFounder, CEO, GM, Manager & Chairman
- Zhixian ChenChief Financial Officer
- Chang-Min WuFinancial Officer, Accounting Officer, Accounting Supervisor & Corporate Governance Officer